OncLive TV

David Sommerhalder, MD, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer.

Russell Pachynski, MD, discusses the ongoing investigation of ARX517 in patients with advanced solid tumors in the phase 1/2 APEX-01 trial.

Muhamad Alhaj Moustafa, MD, MS, discusses the phase 3 SHINE trial, which evaluated ibrutinib given with bendamustine and rituximab in patients with mantle cell lymphoma.

Francisco J. Esteva, MD, PhD, discusses the phase 3 monarchE and NATALEE trials in patients with hormone receptor–positive/HER2-negative breast cancer.

Jue Wang, MD, discusses how to approach testing for molecular alterations in patients with relapsed or refractory urothelial carcinoma.

Omar Abughanimeh, MD, discusses the evolution of targeted therapies for patients with EGFR-positive non-small cell lung cancer.

Amy W. Zhou, MD, discusses combination therapies with ruxolitinib that may contribute to the treatment paradigm for patients with myelofibrosis, highlighting the importance of continued research with phase 3 confirmatory trials for patients with this disease.

Jue Wang, MD, discusses the importance of personalized treatment approaches in patients with relapsed or refractory urothelial carcinoma.

Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, emphasizing the importance of collaborative efforts when approaching gaps in lung cancer care.

Joshua Hurwitz discusses findings from a study investigating the safety of adding multifocal MRI-directed simultaneous integrated boost to stereotactic body radiation therapy in patients with prostate cancer.

Vinai Gondi, MD, discusses efficacy and safety findings from the phase 2/3 NRG-CC003 trial of prophylactic cranial irradiation in patients with small cell lung cancer.

Lynn G. Feun, MD, discusses the evolution of treatment approaches in hepatoceullar carcinoma, the influence of immunotherapies on patient outcomes in this armamentarium, and ongoing avenues of investigation within in the field of HCC management.

Ravi Salgia, MD, PhD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, highlighting unmet needs that remain regarding treatment-related toxicities that can arise with commonly used agents in patients with lung cancer.

Erminia Massarelli, MD, PhD, MS, discusses clinical gaps in lung cancer care that were highlighted at the 2023 Bridging the Gaps in Lung Cancer meeting, emphasizing the importance of molecular testing in patients with small cell lung cancer and collaborations between health care networks in this treatment arena.

Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, highlighting the similarities and differences between treating lung cancer in community oncology settings vs academic medical center settings.

David Sher, MD, discusses efficacy outcomes with daily adaptive radiotherapy with 1-mm planning target volume margins in patients with head and neck squamous cell carcinoma.

Matthew Lunning, DO, FACP, discusses considerations for community oncologists who treat patients with relapsed/refractory follicular lymphoma.

Brian M. Slomovitz, MD, discusses the optimal role for PARP inhibition in patients with ovarian cancer, highlighting its efficacy in those harboring BRCA mutations.

Elisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.

Praveen Vikas, MBBS, discusses the benefits associated with utilizing minimal residual disease detection in breast cancer.

Wade T. Iams, MD, discusses the impact of the phase 3 FLAURA2 trial in patients with EGFR-mutant non–small cell lung cancer, highlighting the notable improvements in progression-free survival that the approach elicits.

Jens Hillengass, MD, PhD, discusses the rationale for investigating exercise and its effect on functional performance in multiple myeloma, and highlights the methods utilized in this study.

John N. Allan, MD, discusses a planned evaluation of obinutuzumab triplet consolidation therapy for patients with chronic lymphocytic leukemia /small lymphocytic lymphoma who remain minimal residual disease–positive after initial treatment with zanubrutinib and venetoclax .

Adam Kittai, MD, discusses key findings from a matching-adjusted, indirect comparison of acalabrutinib with or without obinutuzumab vs zanubrutinib monotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.

Stacey Stein, MD, discusses key considerations when selecting a first-line treatment approach for higher-risk patients with hepatocellular carcinoma, and in what scenarios the combination of atezolizumab and bevacizumab is a viable approach in this population.

Jens Hillengass, MD, PhD, professor, discusses the influence of physical activity on functional performance for patients with multiple myeloma, according to results from a 2-arm, nonrandomized pilot exercise study.

Danielle M. Brander, MD, discusses the primary analysis of the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Catherine C. Coombs, MD, discusses the feasibility of switching from treatment with a covalent BTK inhibitor to a BCL-2 inhibitor vs a different covalent BTK inhibitor in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma treated in a real-world setting.

Jeffrey V. Matous, MD, discusses factors to be considered when determining the optimal sequencing of bispecific antibodies in multiple myeloma.

Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.